MedTrace Logo

Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib

NCT05277935 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-08-26

No results posted yet for this study

Summary

Combining a fitness tracker technology with real-time patient-reported outcome monitoring associated with interventions through a health care app is a novel strategy to evaluate metastatic breast cancer patients using Palbociclib and endocrine treatment.

Conditions

  • Breast Neoplasm Female
  • Quality of Life

Interventions

DEVICE

Use of the WeCancer app combined with the smartwatch.

To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy

Sponsors & Collaborators

  • Beneficência Portuguesa de São Paulo

    lead OTHER

Principal Investigators

  • Graziela Dal Molin, MD · Beneficência Portuguesa de São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-22
Primary Completion
2025-03-01
Completion
2025-03-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05277935 on ClinicalTrials.gov